Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Seo-Yoon Jeong"'
Publikováno v:
International Journal of Human Movement Science. 15:87-98
Autor:
A. Roshak, Chae Won Park, Matthew V. Lorenzi, Seong Gu Heo, Min Hee Hong, Mi Ran Yun, Sun Min Lim, Soo-Hwan Lee, Meena Thayu, Kyoung Ho Pyo, Byoung Chul Cho, Seo Yoon Jeong, Hye Ryun Kim, Seok Young Kim, S.M. Lim, J.C. Curtin, Jiyeon Yun, Jae Hwan Kim, Roland Elmar Knoblauch
Publikováno v:
Cancer Discovery. 10:1194-1209
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activi
Autor:
Seo-Yoon Jeong, Jiyeon Yun, San-Duk Yang, Soo-Hwan Lee, Sangbin Lim, Seok-Young Kim, Min Hee Hong, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho
Publikováno v:
Cancer Research. 81:1106-1106
Background: EGFR-TKI is an established first-line therapy for NSCLC with activating EGFR mutations. Osimertinib, third-generation EGFR TKI, was investigated as a first-in-class drug, but lazertinib(YH25448) was also reported as an outstanding drug wh
Autor:
Jiyeon, Yun, Soo-Hwan, Lee, Seok-Young, Kim, Seo-Yoon, Jeong, Jae-Hwan, Kim, Kyoung-Ho, Pyo, Chae-Won, Park, Seong Gu, Heo, Mi Ran, Yun, Sangbin, Lim, Sun Min, Lim, Min Hee, Hong, Hye Ryun, Kim, Meena, Thayu, Joshua C, Curtin, Roland E, Knoblauch, Matthew V, Lorenzi, Amy, Roshak, Byoung Chul, Cho
Publikováno v:
Cancer discovery. 10(8)
Autor:
Matthew V. Lorenzi, Hye Ryun Kim, Meena Thayu, Ji Min Lee, Seo-Yoon Jeong, Jiyeon Yun, Min Hee Hong, Han Na Kang, Jae Hwan Kim, Soo-Hwan Lee, Roland Elmar Knoblauch, Kyoung Ho Pyo, Chae Won Park, J.C. Curtin, Byoung Chul Cho, Seok-Young Kim
Publikováno v:
Cancer Research. 80:5199-5199
PURPOSE: Although EGFR exon20 insertion (ex20ins) mutations account for 4~12 % of EGFR mutant NSCLC patients, there is no effective and selectable anticancer drugs targeting ex20ins mutations so far due to various variant mutations in ex20ins mutatio
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Han Na Kang, Minsun Hong, A. Roshak, Seo-Yoon Jeong, J.C. Curtin, Jiyeon Yun, Roland Elmar Knoblauch, S.J. Lee, Matthew V. Lorenzi, Meena Thayu, H.R. Kim, Chae Won Park, Byoung Chul Cho
Publikováno v:
Journal of Thoracic Oncology. 14:S397-S398
Publikováno v:
Journal of Distribution Science. 13:59-67
Purpose – The number of consumers adopting a lifestyle of health and sustainability has recently increased with the rise of trends in...
Publikováno v:
Asia-Pacific Journal of Business Venturing and Entrepreneurship. 8:188-202